Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352922 · ClinicalTrials.gov registry record · Phase 4
Randomized Trial of Wound Infiltration With Extended-release Bupivacaine Before Laparoscopic or Robotic Hysterectomy
A Phase 4 study, sponsored by AdventHealth.
- Completed
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT02352922 is a Phase 4 study that has completed, run by AdventHealth. The registered enrollment target is 64 participants.
The verdict
NCT02352922, a Phase 4 study, has completed, sponsored by AdventHealth.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
The investigators are studying ways to improve pain control after surgery. One way to decrease pain is to inject incisions with a numbing medicine (local anesthetic) while in the operating room. There is an FDA approved extended-release version of a commonly used local anesthetic (bupivacaine) that can last for 4 days instead of 6 hours. The investigators are studying whether using the extended-release medication (Exparel) will give better pain relief after laparoscopic and robotic-assisted hysterectomies.
Interventions
- DRUG Liposomal Bupivacaine
- DRUG Bupivacaine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02352922
The ClinicalTrials.gov registry entry for NCT02352922 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal Bupivacaine is the first listed.
NCT02352922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02352922 about?
NCT02352922 is a clinical study titled "Randomized Trial of Wound Infiltration With Extended-release Bupivacaine Before Laparoscopic or Robotic Hysterectomy". The investigators are studying ways to improve pain control after surgery. One way to decrease pain is to inject incisions with a numbing medicine (local anesthetic) while in the operating room. There is an FDA approved extended-release version of a commonly used local anesthetic (bupivacaine) that ...
What is the current status of trial NCT02352922?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2015-07. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02352922?
The interventions under investigation include: Liposomal Bupivacaine (DRUG), Bupivacaine HCl (DRUG).
Who is sponsoring clinical trial NCT02352922?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.